Trials / Terminated
TerminatedNCT02258581
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 241 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-4774 | Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection. |
| DRUG | GS-9620 | Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection. |
| DRUG | Tenofovir disoproxil fumarate (TDF) | Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection. |
Timeline
- Start date
- 2014-12-09
- Primary completion
- 2017-08-14
- Completion
- 2017-08-14
- First posted
- 2014-10-07
- Last updated
- 2017-10-03
Locations
37 sites across 8 countries: United States, Australia, Canada, Hong Kong, India, Italy, New Zealand, South Korea
Source: ClinicalTrials.gov record NCT02258581. Inclusion in this directory is not an endorsement.